- 商品介绍
- 规格参数
- 包装参数
Biochem/physiol Actions
Bioavailable triple acting, selective, high affinity 5-HT6R/5-HT3R dual antagonist and MAO-B reversible inhibitor; anti-AD agent.
PZ-1922 is a piperazinyl-pyrroloquinoline analog with favorable oral absorption and CNS penetration that simultaneously targets 5-HT6R (Ki = 17 nM), 5-HT3R (Ki = 0.45 nM), and MAO-B (pIC50 = 8.93). PZ1922 shows high selectivity over a selected panel of GPCRs, MAO-A and hERG. PZ 1922 effectively reverses cognitive impairment, prevents Aβ-induced memory decline in rodent models of Alzheimer’s disease (AD) (1.5 mg/kg/ip injection) and modulates neuroinflammatory processes.
Disclaimer
Hygroscopic
| Quality Segment | 100 |
| assay | ≥95% (HPLC) |
| form | powder |
| storage condition | desiccated |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | -10 to -25°C |
| SMILES string | ClC1=CC(CN2C=CC3=C2C4=CC=CC=C4N=C3N5CCNCC5)=CC=C1 |
| InChI key | MFUVKDHSDIAPMH-UHFFFAOYSA-N |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
¥ 2528.88
-
询价
-
询价
-
询价
-
¥ 9737.84
-
询价
-
¥ 5725.45
-
¥ 1653.62
-
询价
-
¥ 2268.97
-
¥ 1586.69
-
询价
-
¥ 4614.63
-
¥ 3662.39
-
¥ 44224.19
-
¥ 1799.83
-
询价
-
询价
-
询价
-
询价
微信小程序
7X24小时在线咨询